Neither the first breakthrough therapy designees nor FDA seemed prepared for the operational tempo that was required for the pathway, which has prompted the agency to begin laying out communications expectations for the program.
Ironically, some early breakthrough programs did not include as much dialogue between the agency and sponsor as the concept promised
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?